Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2023

Genmab — April 2023

Planlagt Fastgjort Låst Flyttet Genmab
835 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #94

    Der skulle komme mim8 data til næste år.

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #95

      … fra fase 3 studiet.

      1 Reply Last reply
      0
      • G Offline
        G Offline
        gentogen
        wrote on sidst redigeret af
        #96

        Det har åbenbart været kendt længe. For eksempel her: https://onlinelibrary.wiley.com/doi/10.1111/hae.14118

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #97

          Eller her: https://hemophilianewstoday.com/news/cancer-therapy-daratumumab-can-effectively-lower-inhibitors-hemophilia-a-case-series/

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #98

            Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-positive-topline-data

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #99

              Do we have an estimate for Tepezza sales fy 2023?

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #100

                i can't find anything in my notes, can't remember them giving guidance.. we may get less information once Amgen is in control..

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #101

                  small new trial for Daratumumab in Non-small Cell Lung Cancer With STK11/LKB1 Mutation (not by JNJ) https://clinicaltrials.gov/ct2/show/NCT05807048

                  1 Reply Last reply
                  0
                  • M Offline
                    M Offline
                    MarsFars
                    wrote on sidst redigeret af
                    #102

                    God aften ?

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #103

                      Investeringspodcasten: Fokus på C25 og sidste udkald for SAS
                      https://www.proinvestor.com/boards/111969

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #104

                        Genmab sidst i udsendelsen.

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #105

                          Godmorgen 🙂

                          1 Reply Last reply
                          0
                          • T Offline
                            T Offline
                            transalp
                            wrote on sidst redigeret af
                            #106

                            Go morgen.. 🙂

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              bibob
                              wrote on sidst redigeret af
                              #107

                              God morgen 🙂

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #108

                                Successful treatment with subcutaneous ofatumumab in an adolescent patient with refractory myelin oligodendrocyte glycoprotein-immunoglobulin G-associated disease (MOGAD) https://www.sciencedirect.com/science/article/pii/S2405650223000199?via%3Dihub

                                1 Reply Last reply
                                0
                                • T Offline
                                  T Offline
                                  Teller
                                  wrote on sidst redigeret af
                                  #109

                                  I forhold til retssagen, hvor meget vurderes der at være lagt ind i kursen pt? i begge retninget?

                                  1 Reply Last reply
                                  0
                                  • StockBullS Offline
                                    StockBullS Offline
                                    StockBull
                                    wrote on sidst redigeret af
                                    #110

                                    Den lave PE værdi / kurs indikere markedet har indregnet at Genmab taber voldgiften. Derfor en pæn optur hvis Genmab mod markedets forventning vinder sagen.

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #111

                                      Umuligt at sige hvad der er indregnet, men enig med StockBull i, at opturen må forventes at være langt større ved sejr end nedturen ved tab. Jan har ligeledes flere gange på diverse CC´er sagt, at analytikerne ikke skal indregne noget før sejren er i hus. Så kan vi altid feste over et glas champagne, hvis det skulle ske !

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #112

                                        Jeg gad godt vide om voldgiften har nogen betydning for, hvor stort man tør satse på den nye sygdomsområde.

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #113

                                          Mon ikke vi med lidt held kan holde optrenden lidt med opsigt til ASCO/EHA konferencerne, PDUFA for Epco og lidt andet løst......

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper